

Anti-IGF1R Antibody (Teprotumumab Biosimilar)

Cat. No. AB131


Description	
Reactivities	Human/Cynomolgus
Target	IGF1R
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA
MolecularWeight	49.3 kDa and 23.5 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 µM filtered
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage	
Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target.	

Assay Data


Bis-Tris PAGE



Teprotumumab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data




The purity of Teprotumumab Biosimilar is greater than 95% as determined by SEC-HPLC.

Assay Data

ELISA Data

Teprotumumab Biosimilar ELISA
0.05µg Human IGF1R, His Tag Per Well



Immobilized Human IGF1R, His Tag at 0.5µg/ml (100µl/well) on the plate. Dose response curve for Teprotumumab Biosimilar with the EC50 of 4.3ng/ml determined by ELISA.